Biocon Profile

Established in 1978, Biocon is India's premier biotechnology company. Headquartered in Bangalore Biocon has evolved from an enzyme company to a fully integrated biopharmaceutical enterprise, focused
on healthcare. In 2007, Biocon made a strategic decision to divest its historic enzymes business to Novozymes A/S of Denmark. Biocon now strategically focuses its activities on its bio-pharma business
verticals that include APIs, biologicals and proprietary molecules both commercialized and under development with this divestment, the company mission is to ‘Develop novel & affordable Biotherapeutics
for global markets’.

Biocon Limited and its two subsidiary companies, Syngene International Limited and Clinigene International Limited form a fully integrated biotechnology enterprise specializing in biopharmaceuticals,
custom research and clinical research. Biocon's integrated business approach has enabled the company to establish a significant presence in the global biopharmaceutical market via its product offerings
and customised, high value solutions at any stage in the lifecycle of a drug-from discovery to market. Biocon’s vision is to be an integrated biopharmaceutical enterprise of global distinction.

The company applies its proprietary fermentation technologies to make effective and innovative biomolecules in diabetology, oncology, cardiology and other therapeutic segments. Biocon's products in the
biopharmaceutical category include: anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-oxidants, biologicals, cholesterol-lowering agents, haemostatic agents, hepatoprotective
agents,
immunosuppressants, nutraceuticals and orthopaedic agents.

With its strong focus on R&D Biocon offers services in custom research (Syngene) in the fields of synthetic chemistry and molecular biology in early stage drug discovery and development. Clinical research
(Clinigene) is carried out in the fields of clinical studies and clinical trials.

Biocon Park, inaugurated in June 2006 by President APJ Abdul Kalam comprises an integrated cluster of research laboratories and manufacturing facilities laid out on a 90 acre expanse in Bommasandra
Industrial Area – Phase IV. Built with a total investment of Rs. 650 crores, with further investments to follow, Biocon Park is the single largest capital investment made by Biocon in its 32-year history and is
focused on exports of both bio-pharmaceutical products and research services. The multi-product facilities mainly cater to the following disease segments: cardiovascular, cholesterol reduction,
immunosuppressants in organ transplantation, diabetes and cancer.

Biocon's success has been characterized by an enduring set of corporate values based on innovation, integrity, strong leadership and social responsibility. As India's first and leading biotechnology company
Biocon extends its support to numerous community outreach and corporate citizenship initiatives with special concentration in the areas of healthcare, education and environment. The Biocon Foundation,
set up in 2004 has launched Arogya Raksha Yojana, a unique health initiative for rural India.

Biocon aims to continuously create growth in different areas of the company and is the first company, globally to manufacture human insulin, Insugen® using a Pichia expression system. In addition, in
2006, Biocon launched BIOMAb EGFR™, the first indigenously developed humanized monoclonal antibody for Head & Neck cancer.

General Information

Biocon Limited is a fully integrated biopharmaceutical

company focused on biopharmaceuticals, custom
research and clinical research.

Subsidiary Companies:

Syngene International Limited is a custom research

organisation offering synthetic chemistry and molecular
biology services for early stage drug discovery and
development.

Clinigene International Limited is a clinical research

organisation offering Phase I-IV clinical trials and studies
for novel/generic molecules to international
pharmaceutical majors.

Biocon Biopharmaceuticals Private Limited (BBPL)

began as a joint venture with CIMAB to develop and
market a range of monoclonal antibodies and cancer
vaccines. In March 2010, Biocon acquired CIMAB’s
49% stake and BBPL became a 100% subsidiary.

AxiCorp GmbH is a Friedrichsdorf (Germany) based

pharmaceutical marketing company and is amongst the
fastest growing in Europe. Biocon Limited acquired a
majority stake in AxiCorp GmbH (78%) in February,
2008.

NeoBiocon FZ LLC is a research and marketing

pharmaceutical company based in Abu Dhabi.
Incorporated in January 2008, NeoBiocon is a 50:50 joint
venture with Dr. B.R.Shetty, Managing Director of
NeoPharma, Abu Dhabi.

Intellectual Profile of 4750+ Personnel

Biocon, Syngene and Clinigene together employee approximately 4750 qualified personnel - from biologists, chemists,
medical practitioners, pharmacologists, engineers, finance / legal / marketing analysts, HR generalists to general
administrators. 5% of our employees have PhD degrees, 41% have a master’s degree in science and the remaining are
graduates with a bachelors degree in science, commerce or arts. 15% of Biocon employees are women (across the
group). The employee attrition last quarter was 7% and last year it was over 20%. The average age of the employees is
29 years.

Milestones

- Biocon is India's first biotechnology company, established

  in 1978

- Biocon is India's first biotechnology company to export

  microbial enzymes to USA and Europe

- Biocon is the first biotechnology company to receive ISO

  9001 certification in India

- Syngene, a Biocon subsidiary, is India's first custom

  research company in drug discovery

- Biocon is the first Indian company to be approved by

  US FDA for the manufacture of lovastatin, a
  cholesterol-lowering molecule

- Biocon's proprietary bioreactor, the PlaFractor™, receives a   US patent

- Biocon's subsidiary, Clinigene, has India's first CAP

  (College of American Pathologists) accredited clinical
  research laboratory, setting the benchmark for
  laboratories in India

- Biocon is awarded the Biotech Product and Process

  Development and Commercialisation Award, 2001 by
  the Department of Biotechnology, Ministry of Science
  and Technology, Government of India

- Syngene is awarded the Certificate of Excellence for

  Export Achievement by the Government of India, for
  two consecutive years 2002-2003

- Biocon is the first company, globally to manufacture

  human insulin, INSUGEN®, using a Pichia expression
  system, 2004

- Biocon launches BIOMAb EGFR™ India's first anti-cancer,   therapeutic Monoclonal Antibody-based drug for treating solid
tumors of epithelial origin, such as head & neck cancers, 2006

- Biocon divests its enzymes division to Novozymes, focuses   on biopharmaceuticals, 2007

- Syngene receives "BioServices Company of the Year",

  BioSpectrum Awards, 2007

- Biocon's BIOMAb EGFR™ wins "Product of the Year",

  BioSpectrum Awards, 2007

- Biocon acquires a 78% stake in German pharmaceutical   company, AxiCorp GmbH for a consideration of €30
  Million, 2008

- Biocon launches a Safety Device in the form of pre-filled   syringes for two of its life saving products, GCSF
(granulocyte-  colony stimulating factor) and EPO (Erythropoietin) in   collaboration with Safety Syringes Inc. ERYPRO
Safe™ and   NUFIL Safe™ are the first two drugs that will marketed using   this novel device with other injectable
products to follow in the   future, 2008

- Biocon and Abraxis Bioscience launch ABRAXANE in India for   treatment of Breast Cancer, 2008

- Biocon is ranked among the top 20 global biotechnology   companies (Med Ad News), 2008

- Biocon is the 7th largest biotech employer in the world (Med   Ad News), 2008

- Biocon announced the results of an ascending dose study on   its oral insulin drug (IN-105) at the European Association
for   the Study of Diabetes (EASD) meeting in Rome, 2008

- NeoBiocon and Abraxis Bioscience launch Abraxane in the UAE   for the treatment of Breast Cancer, 2008
- Biocon's Syngene partners with Sapient Discovery to expand   integrated drug discovery offerings, 2009

- Biocon's Syngene and DuPont Crop Protection Forge Alliance   Partnership, 2009

- Bristol-Myers Squibb and Biocon's Syngene open new R&D   Facility at Biocon Park, 2009

- Biocon launches BASALOG - long lasting basal insulin for Type   1 & Type 2 Diabetics, 2009

- Biocon inks partnership with ISB to launch the Biocon Cell for   Innovation Management, 2009

- Biocon Announces Strategic Collaboration with Mylan to enter   the Global Generic Biologics Market, 2009

- Biocon Limited and Amylin Pharmaceuticals entered into a   Global Development and Commercialization Agreement for a
Novel Peptide Hybrid. The Program will focus on the potential   treatment of diabetes, 2009

- Biocon and HCG group of hospitals join hands to fight against   cervical, 2009

- Biocon explores investment in Malaysia in partnership with   BiotechCorp, 2010

- Biocon and Bayer join hands to create awareness for self   monitoring for diabetics, 2010

- Syngene and Endo Pharmaceuticals, USA  to  jointly discover   and develop novel biological drug molecules to fight
cancer,   2010

- Biocon acquires stake of its Cuban partner CIMAB S.A. in their   seven year old JV, Biocon Biopharmaceuticals Pvt. Ltd,
2010

- Biocon and Optimer Pharmaceuticals announce manufacturing   and supply agreement for a novel API, first-in-class
  anti-infective (C. difficile), 2010

Services

Licensing
Biocon collaboratively develops MAbs (Monoclonal Antibodies) and other novel drug delivery systems-based proteins
either in-house or in partnership with other companies.

Contract Manufacturing
Biocon leverages its India cost base together with its extensive expertise and technology platforms to offer competitive,
high quality, custom manufacturing services to a global clientele.

Research Services

Custom Research - Syngene

Chemistry Biology

- Medicinal Chemistry - Molecular Biology

- Library Synthesis - Protein Sciences
- Process R&D - Cell Lines Services
- Custom Manufacturing - Assay Services
- Analytical Services - eADMET&PK
- Polymer Chemistry - Biologics
 
Clinical Research -Clinigene
- Human Pharmacology Unit
- Bioanalytical Research Laboratory
- Central Laboratory
- Clinical Operations
- Medical Writing
- Medical Monitoring & Safety Management
- Pharmacovigilance
- Clinical Data Management & Biostatistics
- Regulatory Services

People

An organisation is as dynamic and effective as its people.

At Biocon, the vast experience of our distinguished Board
of Directors and the strategic focus of the Key
Management Team steer us towards our goals. They are
amply supported by a 4750-strong team of exemplary
bioscientists, engineers and business managers who build
our intellectual capital and drive our growth.
Environment

At Biocon, we respect the fact that our people must

operate in a safe and hazard-free work place and our
facilities adhere to eco-efficient production practices. We
aim to balance business interests with sustainable
development by investing in state-of-the-art technologies
that have minimal environmental impact. Our
commitment to EHS is additionally demonstrated in the
stringent, globally recognised standards we have adopted.
Biocon is ISO 14001:2004 certified for environmental
protection and OHSAS 18001: 2000 approved for good
practices vis-à-vis occupational health and safety at the
workplace.
Strategic Alliances

Biocon and Optimer Pharmaceuticals announce

manufacturing and supply agreement for a novel API,
first-in-class anti-infective (C. difficile)
BIOCON - OPTIMER PHARMACEUTICALS: 2010
Syngene and Endo Pharmaceuticals, USA  to  jointly
discover and develop novel biological drug molecules to
fight cancer
SYNGENE - ENDO PHARMACEUTICALS: 2010
Biocon Announces Strategic Collaboration with Mylan to
enter the Global Generic Biologics Market.
BIOCON - MYLAN: 2009
Biocon inks partnership with ISB to launch the Biocon
Cell for Innovation Management.
BIOCON - ISB: 2009
Syngene and DuPont Crop Protection Forge Alliance
Partnership.
SYNGENE - DuPONT CROP PROTECTION: 2009
Syngene partners with Sapient Discovery to expand
integrated drug discovery offerings.
SYNGENE - SAPIENT DISCOVERY: 2009
Acquisition for the marketing and distribution of a range
of pharmaceuticals in Germany and Europe.
BIOCON-AXICORP: 2008
Partnership for the co-development of immunoconjugates
for targeted immunotherapy of cancers and infectious
diseases
BIOCON- IATRICa: 2008
Licensing agreement for G-CSF in North Anerica and the
European union and for the commercialisation of
ABRAXANE in India
BIOCON - ABRAXIS: 2007
Partnership for Greater Focus in Biotechnology and
Biosciences Research
BIOCON- DEAKIN UNIVERSITY: 2007
Partnership for research discovery and development in
India SYNGENE- BRISTOL-MYERS SQUIBB: 2007
Exclusive Marketing License for BIOMAb EGFR™ for
Pakistan BIOCON-FEROZSONS: 2007
Partnership to Manufacture and Market
Biopharmaceuticals BIOCON- NEOPHARMA: 2007
Partnership to Develop Virulence Blockers
SYNGENE - INNATE PHARMACEUTICALS: 2006
Exclusive Marketing Agreement for INSUGEN® in
Chinese markets
BIOCON- BAYER HEALTHCARE: 2006
Licensing Agreement to Develop and Market Intranasal
Insulin Spray
BIOCON-BENTLEY: 2005
Collaboration in Research and Research-Education
BIOCON-KAROLINSKA INSTITUTE: 2005
Partnership to Discover and Develop Therapeutic
Antibodies
BIOCON-VACCINEX: 2004
Partnership for the Co-development of Immunotherapy &
Monoclonal Antibodies
BIOCON-CIMAB: 2003
Contact
Corporate Headquarters
Bangalore

20th KM Hosur Road

Electronics City
Bangalore 560 100
Intellectual Profile of 4750+ Personnel

Products & Services

“Biocon’s impressive range of products and partnered services continue to build a robust pipeline of biosimilar and discovery-led biologicals programs in oncology, nephrology,
diabetes and autoimmune diseases.”
- Sandeep Rao, Vice President, Business Development
Over the years, we have systematically leveraged our technology platforms from enzymes to small molecules to recombinant proteins and antibodies. Through partnerships and alliances, Biocon has
strategically moved up the value chain from supplying pharmaceutical bulk actives to developing proprietary molecules and our own branded formulations.

In the areas of custom and clinical research services, collaborative partnerships with complementary biotechnology and pharmaceutical companies are yielding rich results. We believe these partnerships
will positively impact any and all phases of our discovery portfolio.

Differentiation and a high degree of innovation distinguish all our products and services. Combined with India’s value advantage, they enable us to develop and deliver novel and affordable therapeutics for
global unmet medical needs.

Biopharmaceuticals

Biocon is among few companies in the world with a diverse scientific skill base and advanced manufacturing capabilities for the development and commercialisation of biopharmaceuticals. We offer a range
of products from fermentation derived small molecules to recombinant proteins and antibodies. In the specialised and price-sensitive field of custom manufacturing, we provide high quality, cost-
competitive services to domestic and international pharmaceutical companies. Moving up the value chain, we have built a robust branded formulations business that is rapidly expanding our global market
presence

Biopharmaceuticals

  Dosage Forms

Based on our strong presence in the pharmaceutical API business, Biocon has now decided to vertically integrate by moving into the field of branded formulations. Insulin and statins are two flagship brands
that will enable Biocon to offer a range of fast moving products in the therapeutic segments of cardiology and diabetes. Biocon's INSUGEN spearheads our recombinant human insulin initiative.

Licensing

Biocon is continuously leveraging its rich pool of research talent to pursue its mid-to-long-term goals to collaboratively develop MAbs (Monoclonal Antibodies) and other novel drug delivery systems-based
proteins either in-house or in partnership with other companies. Such symbiotic co-development activities will enable Biocon to out-license the researched product for global markets. As we focus our
resources on various R&D programs in key disease segments, we believe out-licensing is the way forward and will be a significant future growth driver for the company.

Contract Manufacturing

Small-to-medium sized pharmaceutical and biotech companies are positioned to bring 50 percent of new drug molecules to market in the next decade. With escalating R&D costs and the long path to new
medicine, these companies are forced to view outsourcing or contract services as an important part of their manufacturing strategy.

Biocon leverages its India cost-base together with its extensive expertise and technology platforms to offer competitive, high quality, custom manufacturing services to a global clientele. Our full set of
manufacturing capabilities, include mammalian cell culture fermentation, microbial cell culture fermentation, synthetic chemistry, formulation development for solid dosage (tablets and capsules) for
immediate and modified release, injectibles (vials, cartridges, lyophilized and pre filled syringes) and a fill finish facility. Inspected by US FDA on multiple occasions, our facilities inspected by international
regulators including USFDA, EU Inspector, BfArM and Anvisa us partners of choice for companies seeking innovate solutions for their medication delivery needs.

   
Research Services

High levels of innovation and increased productivity are imperatives of the global healthcare industry. To meet this twin
  demand, Syngene, our custom research organisation and Clinigene, our clinical research company works in partnership with
complementary biotechnology and pharmaceutical companies. We believe these partnerships will positively impact all
phases of our discovery portfolio. We are also confident that our well-structured alliances will mitigate the risk of discovery
and encourage a stimulating environment of continuous knowledge creation.